These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 8877917

  • 1. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
    Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Gerber NJ.
    J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
    [Abstract] [Full Text] [Related]

  • 2. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes.
    Seitz M, Zwicker M, Loetscher P.
    Arthritis Rheum; 1998 Nov; 41(11):2032-8. PubMed ID: 9811059
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
    Robak T, Gladalska A, Stepień H.
    Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
    [Abstract] [Full Text] [Related]

  • 7. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints.
    Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M.
    Eur J Immunol; 1992 Jul; 22(7):1907-12. PubMed ID: 1320571
    [Abstract] [Full Text] [Related]

  • 8. Production of interleukin (IL)-1beta, IL-1 receptor antagonist and IL-10 by blood mononuclear cells in chronic arthritis.
    Andersen LS, Petersen J, Bendtzen K.
    Cytokine; 2000 Jan; 12(1):62-8. PubMed ID: 10623444
    [Abstract] [Full Text] [Related]

  • 9. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients.
    Rogy MA, Coyle SM, Oldenburg HS, Rock CS, Barie PS, Van Zee KJ, Smith CG, Moldawer LL, Lowry SF.
    J Am Coll Surg; 1994 Feb; 178(2):132-8. PubMed ID: 8173722
    [Abstract] [Full Text] [Related]

  • 10. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K, Segami N, Sun W, Sato J, Fujimura K.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
    [Abstract] [Full Text] [Related]

  • 11. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects.
    Gao IK, Scholz P, Boehme MW, Norden C, Lemmel EM.
    Rheumatol Int; 2002 Jun; 22(2):45-51. PubMed ID: 12070674
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W.
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [Abstract] [Full Text] [Related]

  • 15. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment.
    Seitz M, Zwicker M, Wider B.
    J Rheumatol; 2001 Mar; 28(3):496-501. PubMed ID: 11296948
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of proinflammatory cytokine inhibitors (sTNFR I, sTNFR II, IL-1 ra), anti-inflammatory cytokines (IL-10, IL-13) and activation of neutrophils after burn-induced inflammation.
    Sikora JP, Chlebna-Sokół D, Andrzejewska E, Chrul S, Polakowska E, Wysocka A, Sikora A.
    Scand J Immunol; 2008 Aug; 68(2):145-52. PubMed ID: 18702744
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J.
    Scand J Rheumatol; 2006 Aug; 35(3):182-8. PubMed ID: 16766364
    [Abstract] [Full Text] [Related]

  • 18. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis.
    Cutolo M, Bisso A, Sulli A, Felli L, Briata M, Pizzorni C, Villaggio B.
    J Rheumatol; 2000 Nov; 27(11):2551-7. PubMed ID: 11093433
    [Abstract] [Full Text] [Related]

  • 19. Disease activity and cytokine production in mitogen-stimulated peripheral blood mononuclear cells from patients with rheumatoid arthritis.
    Uppal SS, Raghupathy R, Hayat SJ, Longenecker JC, Abraham M, Rawoot P.
    Med Princ Pract; 2010 Nov; 19(1):33-9. PubMed ID: 19996617
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts.
    Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M.
    Eur J Immunol; 1995 Apr; 25(4):1129-32. PubMed ID: 7737285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.